

From openstatsware & pharmaverse to a full R submission

J-P Perttola

People and Products Leader - Analytical Data Science Enabling Platform

F. Hoffmann-La Roche Ltd PD Data Sciences Basel, Switzerland



Disclaimer:

Presented opinions are my own

...and it might also be helpful to know that with


these opinions I am not an outlier (anymore)

openstatsware is a scientific working group of the American Statistical Association (ASA)
Biopharmaceutical section (BIOP) and a European Special Interest Group (SIG) sponsored by
Statisticians in the Pharmaceutical Industry (PSI) and the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI).

Our goals are to:

- Engineer selected R-packages to fill in gaps in the open-source statistical software landscape, and to promote software tools designed by the working group through publications, conference presentations, workshops, and training courses.
- **Develop good SWE practices** for engineering high-quality statistical software and promote their use in the broader Biostatistics community via public training materials.
- Communicate and collaborate with other R software initiatives including via the R Consortium.







Brief history of R submissions

"Just because they say it's impossible doesn't mean you can't do it."

— Roger Bannister

Use of Open Source languages in FDA NDAs (by Phil Bowsher)

<u>GitHub - philbowsher/Open-Source-in-New-Drug-Applications-NDAs-FDA</u>

Novo Nordisk's Journey to an R based FDA Submission (September 12th 2023)

Roche's End-to-End R Journey to Submission (September 10th 2024)

What other pieces of the puzzle were needed? (Roche/GNE perspective)

Our Roche/GNE approach



Primary programming:

R

CRAN

Pharmaverse

OAK (SDTM)

Admiral (ADaM)

NEST (TLGs)





Assembling the puzzle further




Goal: Submission packages that are more user friendly to build and consume, sustainably created Internally

- Hiring R talent (started > 10 years ago)
- Building stable, resilient and business connected R package development teams
- Upskilling our data scientists with R & new toolkit (lately assisted by new LLM tools)
- Approval to open source all significant parts from upper management and legal department
- Build & roll out language agnostic Statistical Computing Environment same workflow for all languages
- Create a validated R package repository
- Align exploratory and regulatory environment and workflows
- Automation, parallelization etc
- **FAIR**ness by design (Findable, Accessible, Interoperable, Reusable)

Externally

- R validation hub
- **■** Good software engineering practices
- R consortium submission working group <u>pilots</u>
- CAMIS
- New mindset of collaborating & learning together
- What to do and what not to do when building effective collaborations





Validation/risk management

We are confident that we have solved this topic (for ourselves)

There is **new complexity** coming from using R but it **is manageable**.

Cost-wise, there is some **additional burden** coming from risk managing the **validated R repository** but if that is done on high enough organizational level (or as an industry collaboration) the impact is low and **offset by the benefits**.


On the positive side, for example unit testing and general reproducibility are currently on a higher level than before.

Is this really viable cost-wise?



We obviously think that in the long term it is - and none of the reasons include R being free

- No need to anymore design, develop, test, maintain and document company specific tools for SDTM, ADaM and TLG generation etc.
- We think that by creating the tools and learning collaboratively we can
 - Get the submissions created faster, better and without burnouts
 - Make the submission packages more review friendly & transparent to better support the health authorities and this will eventually (in some cases) lead getting the medicine to patients faster.
- Reduced re-training need (and error & stress reduction) as companies and CROs will share tools.
- ..





What have we learned about collaboration?



- Be open, build trust, simplify but leave room for alternative ways
- Internal and external collaboration network is important
 - "Rising tide lifts all boats."
- We see that in some organizations the structure supports this kind of approach better but in some not so well
 - You might need to "Lift as you climb."
- Many contributors have been struck how enjoyable the collaboration across companies has been -> engagement, retention
 - "Alone we can do so little; together we can do so much."

"It always seems impossible until it's done."

- Nelson Mandela



I am not an R developer in a pharma company - why would I care about this?

- I am not an R developer either and yet I feel that I can make a difference in this space by contributing in various ways internally and externally.
- With pharmaverse/openstatsware we are creating something that supersedes any individual company. We believe ultimately this will greatly benefit the patients.
- There are many ways you can help for example just by raising awareness or by creating the space and possibility for your colleagues to contribute.
- Personal note: If I have an opportunity to assist a fellow human being who needs the help of a medicine from another company than Roche I would feel bad not to do so. These collaborations are that opportunity.



Triftbrücke

10

100% worth the grueling hike to get up. Public transport is a bit spotty to get to and from the hike start as well, but the views and bridge are much worth it

Doing now what patients need next



Links to additional information

Validation/Risk management general:

https://www.r-project.org/doc/R-FDA.pdf https://www.pharmar.org/white-paper/

Validation/Risk management at Roche/Genentech:

R/Pharma 2022 Day 2: Coline Zeballos & Doug Kelkhoff. Roche's approach to software validation

R/Pharma 2021 Day 1. Coline Zeballos. R Package Validation at Roche

Coline Zeballos - Ensuring the quality of your R packages for regulatory submissions

Across company efforts to create a validated R package repository:

<u>Developing a Cross Industry Repository of R Packages for Regulatory Use</u>
<u>Juliane Manitz & Coline Zeballos - Updates from the R Validation Hub: Towards a Pharma Repository</u>

General info:

CDISC Open Source Alliance

R and its rising role - The Effective Statistician - in association with PSI

Pharmaverse:



<u>All pharmaverse packages</u>

<u>Tips for First Time Contributors</u>

Simplifying Clinical Data Dashboards with {teal} and {pharmaverseadam}

Pharmaverse Blogs

Pharmaverse Youtube channel

R package specific (based on the Roche/GNE workflow):

<u>Example teal apps</u> (easy to try out - includes full source code generation)

A Complete Guide to Getting Started with teal

Nest TLG catalog (with interactive WebR)

Instructions how to try out admiral

CDISC OAK SDTM automation project

To be open sourced soon: {teal.builder} Sanofi's extension of teal

Free coursera course PT 1: Making Data Science Work for Clinical Reporting

Free coursera course PT 2: Hands On Clinical Reporting Using R

Regulatory submissions with R:

R consortium submissions working group pilots https://www.appsilon.com/post/first-r-based-submission-to-fda-by-novo-nordisk



Good software engineering practices for developing statistical packages - talks by Daniel Sabanés Bové:

Minimum Viable Good Practices for High Quality Statistical Software Packages - Daniel Sabanés Bové

<u>Daniel Sabanes Bove - Why we Need to Improve Software Engineering in Biostatistics</u>

Improving Software Engineering in Biostatistics with Daniel Sabanés Bové

From the Statistical Method to the R Package - The {mmrm} Example

Statistical Software Engineering 101: Unit Testing for R Developers - The Basics

R/Pharma 2020 Day 1. Daniel Sabanes Bove. Mixed Models with Repeated Measures in R and Shiny